CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 93 filers reported holding CYTOSORBENTS CORP in Q4 2021. The put-call ratio across all filers is 0.50 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,800 | -47.6% | 10,000 | 0.0% | 0.02% | -40.7% |
| Q2 2023 | $35,900 | +6.5% | 10,000 | 0.0% | 0.03% | +3.8% |
| Q1 2023 | $33,700 | +117.4% | 10,000 | 0.0% | 0.03% | +116.7% |
| Q4 2022 | $15,500 | +10.7% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $14,000 | -36.4% | 10,000 | 0.0% | 0.01% | -33.3% |
| Q2 2022 | $22,000 | -31.2% | 10,000 | 0.0% | 0.02% | -14.3% |
| Q1 2022 | $32,000 | -23.8% | 10,000 | 0.0% | 0.02% | -22.2% |
| Q4 2021 | $42,000 | -48.1% | 10,000 | 0.0% | 0.03% | -55.0% |
| Q3 2021 | $81,000 | +6.6% | 10,000 | 0.0% | 0.06% | +7.1% |
| Q2 2021 | $76,000 | -12.6% | 10,000 | 0.0% | 0.06% | -18.8% |
| Q1 2021 | $87,000 | +8.8% | 10,000 | 0.0% | 0.07% | 0.0% |
| Q4 2020 | $80,000 | 0.0% | 10,000 | 0.0% | 0.07% | -4.2% |
| Q3 2020 | $80,000 | -19.2% | 10,000 | 0.0% | 0.07% | -33.9% |
| Q2 2020 | $99,000 | +28.6% | 10,000 | 0.0% | 0.11% | +17.2% |
| Q1 2020 | $77,000 | +102.6% | 10,000 | 0.0% | 0.09% | +126.8% |
| Q4 2019 | $38,000 | – | 10,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 450,000 | $846,000 | 0.90% |
| Skylands Capital, LLC | 2,944,670 | $5,535,980 | 0.84% |
| Sargent Investment Group, LLC | 1,257,048 | $2,363,250 | 0.57% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 197,940 | $372,127 | 0.52% |
| Avenir Corp | 2,717,397 | $5,108,706 | 0.48% |
| Granahan Investment Management | 1,552,393 | $2,918,499 | 0.10% |
| Seelaus Asset Management LLC | 20,450 | $38,446 | 0.04% |
| HighMark Wealth Management LLC | 10,000 | $18,800 | 0.02% |
| Key Client Fiduciary Advisors, LLC | 13,000 | $24,440 | 0.02% |
| Eudaimonia Partners, LLC | 23,500 | $44,180 | 0.01% |